BR112018016396A2 - composto, composição farmacêutica, uso de um composto, e, método para tratar um distúrbio - Google Patents
composto, composição farmacêutica, uso de um composto, e, método para tratar um distúrbioInfo
- Publication number
- BR112018016396A2 BR112018016396A2 BR112018016396A BR112018016396A BR112018016396A2 BR 112018016396 A2 BR112018016396 A2 BR 112018016396A2 BR 112018016396 A BR112018016396 A BR 112018016396A BR 112018016396 A BR112018016396 A BR 112018016396A BR 112018016396 A2 BR112018016396 A2 BR 112018016396A2
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- disorder
- treating
- pharmaceutical composition
- compounds
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 abstract 1
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 abstract 1
- 108091000080 Phosphotransferase Proteins 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 102000020233 phosphotransferase Human genes 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/76—Nitrogen atoms to which a second hetero atom is attached
Abstract
a invenção está direcionada a certos novos compostos. especificamente, a invenção está direcionada a compostos da fórmula (i): (i) e sais dos mesmos. os compostos da invenção são inibidores da atividade da cinase, em particular da atividade da pi3 cinase.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1602527.2A GB201602527D0 (en) | 2016-02-12 | 2016-02-12 | Chemical compounds |
GB1602527.2 | 2016-02-12 | ||
PCT/EP2017/052954 WO2017137535A1 (en) | 2016-02-12 | 2017-02-10 | Chemical compounds as inhibitors of kinase activity |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112018016396A2 true BR112018016396A2 (pt) | 2018-12-18 |
BR112018016396B1 BR112018016396B1 (pt) | 2023-11-14 |
Family
ID=55697605
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112018016396-1A BR112018016396B1 (pt) | 2016-02-12 | 2017-02-10 | Composto, composição farmacêutica, e, uso de um composto |
Country Status (15)
Country | Link |
---|---|
US (2) | US10457674B2 (pt) |
EP (1) | EP3414228B1 (pt) |
JP (1) | JP6916195B2 (pt) |
KR (1) | KR20180105726A (pt) |
CN (1) | CN108884046B (pt) |
AR (1) | AR107570A1 (pt) |
AU (1) | AU2017218530A1 (pt) |
BR (1) | BR112018016396B1 (pt) |
CA (1) | CA3013404A1 (pt) |
ES (1) | ES2786948T3 (pt) |
GB (1) | GB201602527D0 (pt) |
RU (1) | RU2018127494A (pt) |
TW (1) | TW201738238A (pt) |
UY (1) | UY37121A (pt) |
WO (1) | WO2017137535A1 (pt) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW201811766A (zh) * | 2016-08-29 | 2018-04-01 | 瑞士商諾華公司 | N-(吡啶-2-基)吡啶-磺醯胺衍生物及其用於疾病治療之用途 |
GB201712081D0 (en) * | 2017-07-27 | 2017-09-13 | Glaxosmithkline Ip Dev Ltd | Chemical compounds |
KR102130254B1 (ko) | 2019-10-15 | 2020-07-03 | 주식회사 실리콘사피엔스 | 대상자 고유의 혈관에 대한 혈류 시뮬레이션 방법 및 장치 |
Family Cites Families (76)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5552438A (en) | 1992-04-02 | 1996-09-03 | Smithkline Beecham Corporation | Compounds useful for treating allergic and inflammatory diseases |
CA2361954C (en) | 1995-04-14 | 2003-07-08 | Smithkline Beecham Corporation | Metered dose inhaler for albuterol |
DE19723722A1 (de) | 1997-05-30 | 1998-12-10 | Schering Ag | Nichtsteroidale Gestagene |
TW533865U (en) | 1997-06-10 | 2003-05-21 | Glaxo Group Ltd | Dispenser for dispensing medicament and actuation indicating device |
AU9281298A (en) | 1997-10-01 | 1999-04-23 | Kyowa Hakko Kogyo Co. Ltd. | Benzodioxole derivatives |
US6506766B1 (en) | 1998-02-13 | 2003-01-14 | Abbott Laboratories | Glucocortiocoid-selective antinflammatory agents |
US6255303B1 (en) | 1998-03-14 | 2001-07-03 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Phthalazinone PDE III/IV inhibitors |
US6352152B1 (en) | 1998-12-18 | 2002-03-05 | Smithkline Beecham Corporation | Method and package for storing a pressurized container containing a drug |
US6315112B1 (en) | 1998-12-18 | 2001-11-13 | Smithkline Beecham Corporation | Method and package for storing a pressurized container containing a drug |
US6119853A (en) | 1998-12-18 | 2000-09-19 | Glaxo Wellcome Inc. | Method and package for storing a pressurized container containing a drug |
US6390291B1 (en) | 1998-12-18 | 2002-05-21 | Smithkline Beecham Corporation | Method and package for storing a pressurized container containing a drug |
CA2371273A1 (en) | 1999-05-04 | 2000-11-09 | Andrew Fensome | Tetracyclic progesterone receptor modulator compounds and methods |
ES2165768B1 (es) | 1999-07-14 | 2003-04-01 | Almirall Prodesfarma Sa | Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen. |
CO5180649A1 (es) | 1999-09-01 | 2002-07-30 | Abbott Lab | Antagonistas de los receptores de los glucocorticoides para el tratamiento de la diabetes para el tratamiento de la diabetes |
OA11558A (en) | 1999-12-08 | 2004-06-03 | Advanced Medicine Inc | Beta 2-adrenergic receptor agonists. |
WO2001083481A1 (fr) * | 2000-04-27 | 2001-11-08 | Yamanouchi Pharmaceutical Co., Ltd. | Derives d'imidazopyridine |
EP1305329B2 (en) | 2000-08-05 | 2015-03-18 | Glaxo Group Limited | 6.alpha.,9.alpha.-difluoro-17.alpha.-(2-furanylcarboxyl)oxy-11.beta.-hydroxy-16.alpha.-methyl-3-oxo-androst-1,4-diene-17-carbothioic acid s-fluoromethyl ester as an anti-inflammatory agent |
US6484903B2 (en) | 2001-01-09 | 2002-11-26 | Riverwood International Corporation | Carton with an improved dispensing feature in combination with a unique handle |
GB0103630D0 (en) | 2001-02-14 | 2001-03-28 | Glaxo Group Ltd | Chemical compounds |
ATE365720T1 (de) | 2001-03-08 | 2007-07-15 | Glaxo Group Ltd | Agonisten von beta-adrenorezeptoren |
ATE381537T1 (de) | 2001-03-22 | 2008-01-15 | Glaxo Group Ltd | Formanilid-derivative als beta2-adrenorezeptor- agonisten |
BR0209271A (pt) | 2001-04-30 | 2004-06-15 | Glaxo Group Ltd | Composto, uso de um composto composição farmacêutica, formulação em aerossol farmacêutica, método para o tratamento de um paciente humano ou animal com uma condição inflamatória e/ou alérgica, e, processo para a preparação de um composto |
US20040248867A1 (en) | 2001-06-12 | 2004-12-09 | Keith Biggadike | Novel anti-inflammatory 17.alpha.-heterocyclic-esters of 17.beta.carbothioate androstane derivatives |
SI1425001T1 (sl) | 2001-09-14 | 2009-04-30 | Glaxo Group Ltd Glaxo Welcome | Fenetanolaminski derivati za zdravljenje respiratornih bolezni |
US6653323B2 (en) | 2001-11-13 | 2003-11-25 | Theravance, Inc. | Aryl aniline β2 adrenergic receptor agonists |
CA2472746A1 (en) | 2002-01-14 | 2003-07-24 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical formulations containing them and uses thereof |
AU2003214879B2 (en) | 2002-01-22 | 2008-02-07 | The Regents Of The University Of California | Non-steroidal ligands for the glucocorticoid receptor, compositions and uses thereof |
GB0204719D0 (en) | 2002-02-28 | 2002-04-17 | Glaxo Group Ltd | Medicinal compounds |
ES2298508T3 (es) | 2002-03-26 | 2008-05-16 | Boehringer Ingelheim Pharmaceuticals Inc. | Mimeticos de glucocorticoides, metodos para prepararlos, composiciones farmaceuticas y sus usos. |
CA2477764A1 (en) | 2002-03-26 | 2003-10-09 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
DE10215316C1 (de) | 2002-04-02 | 2003-12-18 | Schering Ag | Chinolin- und Isochinolin-Derivate, ein pharmazeutisches Mittel und ihre Verwendung als Entzündungshemmer |
DE60335869D1 (de) | 2002-04-11 | 2011-03-10 | Merck Sharp & Dohme | 1h-benzo(f)indazol-5-yl-derivate als selektive glucocorticoid-rezeptor-modulatoren |
EP1497261B1 (en) | 2002-04-25 | 2007-12-19 | Glaxo Group Limited | Phenethanolamine derivatives |
US7186864B2 (en) | 2002-05-29 | 2007-03-06 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
US7074806B2 (en) | 2002-06-06 | 2006-07-11 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
PT1521733E (pt) | 2002-07-08 | 2014-10-29 | Pfizer Prod Inc | Moduladores do recetor de glucocorticoides |
WO2004009017A2 (en) | 2002-07-18 | 2004-01-29 | Bristol-Myers Squibb Company | Modulators of the glucocorticoid receptor and method |
GB0217225D0 (en) | 2002-07-25 | 2002-09-04 | Glaxo Group Ltd | Medicinal compounds |
CA2496175A1 (en) | 2002-08-21 | 2004-03-04 | Boehringer Ingelheim Pharmaceuticals, Inc. | Substituted hihydroquinolines as glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
GB0220730D0 (en) | 2002-09-06 | 2002-10-16 | Glaxo Group Ltd | Medicinal compounds |
GB0230045D0 (en) | 2002-12-23 | 2003-01-29 | Glaxo Group Ltd | Compounds |
PL375993A1 (en) | 2002-09-16 | 2005-12-12 | Glaxo Group Limited | Pyrazolo[3,4-b]pyridine compounds, and their use as phosphodiesterase inhibitors |
AU2003270783C1 (en) | 2002-09-20 | 2010-05-20 | Merck Sharp & Dohme Corp. | Octahydro-2-H-naphtho[1,2-F] indole-4-carboxamide derivatives as selective glucocorticoid receptor modulators |
GB0224084D0 (en) | 2002-10-16 | 2002-11-27 | Glaxo Group Ltd | Novel compounds |
AU2003298094A1 (en) | 2002-10-22 | 2004-05-13 | Glaxo Group Limited | Medicinal arylethanolamine compounds |
GB0225030D0 (en) | 2002-10-28 | 2002-12-04 | Glaxo Group Ltd | Medicinal compounds |
ATE390407T1 (de) | 2002-10-28 | 2008-04-15 | Glaxo Group Ltd | Phenethanolamin-derivate zur behandlung von atemwegserkrankungen |
GB0225535D0 (en) | 2002-11-01 | 2002-12-11 | Glaxo Group Ltd | Medicinal compounds |
GB0225540D0 (en) | 2002-11-01 | 2002-12-11 | Glaxo Group Ltd | Medicinal compounds |
TWI328009B (en) | 2003-05-21 | 2010-08-01 | Glaxo Group Ltd | Quinoline derivatives as phosphodiesterase inhibitors |
GB0316290D0 (en) | 2003-07-11 | 2003-08-13 | Glaxo Group Ltd | Novel compounds |
NZ556424A (en) | 2003-10-14 | 2008-12-24 | Glaxo Group Ltd | Muscarinic Acetylcholine receptor antagonists |
EP1699512B1 (en) | 2003-11-03 | 2012-06-20 | Glaxo Group Limited | A fluid dispensing device |
PE20050489A1 (es) | 2003-11-04 | 2005-09-02 | Glaxo Group Ltd | Antagonistas de receptores de acetilcolina muscarinicos |
US20070111995A1 (en) | 2003-12-19 | 2007-05-17 | Allen David G | Pyrazolo [3,4-B] pyridine Compounds and Their Use as Phosphodiesterase Inhibitors |
GB0405937D0 (en) | 2004-03-16 | 2004-04-21 | Glaxo Group Ltd | Compounds |
GB0405933D0 (en) | 2004-03-16 | 2004-04-21 | Glaxo Group Ltd | Compounds |
EP1735314A1 (en) | 2004-03-16 | 2006-12-27 | Glaxo Group Limited | Pyrazolo[3,4-b]pyridine compound, and its use as a pde4 inhibitor |
UY28871A1 (es) | 2004-04-27 | 2005-11-30 | Glaxo Group Ltd | Antagonistas del receptor de acetilcolina muscarinico |
WO2006000401A1 (en) | 2004-06-28 | 2006-01-05 | Glaxo Group Limited | Substituted oxazines as glucocorticoid receptor modulators |
WO2006000398A1 (en) | 2004-06-28 | 2006-01-05 | Glaxo Group Limited | 2,3-benzoxazin derivatives as non-steroidal glucocorticoid receptor modulators |
GB0418045D0 (en) | 2004-08-12 | 2004-09-15 | Glaxo Group Ltd | Compounds |
MX2007004465A (es) | 2004-10-19 | 2007-05-07 | Hoffmann La Roche | Derivados de quinolina. |
ATE517908T1 (de) | 2005-01-10 | 2011-08-15 | Glaxo Group Ltd | Androstan-17-alpha-carbonat-derivate zur verwendung bei der behandlung allergischer und entzündlicher zustände |
US20090124588A1 (en) | 2005-01-10 | 2009-05-14 | Glaxo Group Limited | Androstane 17-Alpha-Carbonate for Use in the Treatment of Inflammatory and Allergic Conditions |
ES2446417T3 (es) * | 2007-03-23 | 2014-03-07 | Amgen Inc. | Derivados de quinolina o quinoxalina sustituidos en 3 y su uso como inhibidores de fosfatidilinositol 3-cinasa (PI3K) |
BRPI0810641A2 (pt) * | 2007-04-12 | 2019-09-24 | Hoffmann La Roche | "compostos farmacêuticos". |
JP2011500823A (ja) | 2007-10-22 | 2011-01-06 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | Pi3キナーゼ阻害物質としてのピリドスルホンアミド誘導体 |
GB2465405A (en) * | 2008-11-10 | 2010-05-19 | Univ Basel | Triazine, pyrimidine and pyridine analogues and their use in therapy |
SG179085A1 (en) * | 2009-09-09 | 2012-04-27 | Avila Therapeutics Inc | Pi3 kinase inhibitors and uses thereof |
MY173795A (en) * | 2009-11-05 | 2020-02-24 | Incozen Therapeutics Pvt Ltd | Novel benzopyran kinase modulators |
CN105859689A (zh) * | 2009-12-28 | 2016-08-17 | 财团法人生物技术开发中心 | 作为mTOR和PI3K抑制剂的新颖嘧啶化合物 |
CA2829558A1 (en) * | 2011-03-09 | 2012-09-13 | Celgene Avilomics Research, Inc. | Pi3 kinase inhibitors and uses thereof |
CN103539777B (zh) * | 2012-07-13 | 2016-03-02 | 广东东阳光药业有限公司 | Pi3激酶调节剂及其使用方法和用途 |
CN104870017B (zh) * | 2012-11-08 | 2020-08-14 | 理森制药股份公司 | 含有PDE4抑制剂和PI3δ或双重PI3δ-γ激酶抑制剂的药物组合物 |
CN104402861A (zh) * | 2014-11-07 | 2015-03-11 | 中国人民解放军第二军医大学 | 苯磺酰胺衍生物、制备方法及治疗用途 |
-
2016
- 2016-02-12 GB GBGB1602527.2A patent/GB201602527D0/en not_active Ceased
-
2017
- 2017-02-09 AR ARP170100322A patent/AR107570A1/es unknown
- 2017-02-10 EP EP17704257.9A patent/EP3414228B1/en active Active
- 2017-02-10 RU RU2018127494A patent/RU2018127494A/ru not_active Application Discontinuation
- 2017-02-10 US US16/073,355 patent/US10457674B2/en active Active
- 2017-02-10 JP JP2018542238A patent/JP6916195B2/ja active Active
- 2017-02-10 AU AU2017218530A patent/AU2017218530A1/en not_active Abandoned
- 2017-02-10 UY UY0001037121A patent/UY37121A/es not_active Application Discontinuation
- 2017-02-10 KR KR1020187026341A patent/KR20180105726A/ko unknown
- 2017-02-10 TW TW106104541A patent/TW201738238A/zh unknown
- 2017-02-10 ES ES17704257T patent/ES2786948T3/es active Active
- 2017-02-10 BR BR112018016396-1A patent/BR112018016396B1/pt active IP Right Grant
- 2017-02-10 CN CN201780021258.1A patent/CN108884046B/zh active Active
- 2017-02-10 WO PCT/EP2017/052954 patent/WO2017137535A1/en active Application Filing
- 2017-02-10 CA CA3013404A patent/CA3013404A1/en active Pending
-
2019
- 2019-09-17 US US16/572,917 patent/US10793559B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
EP3414228A1 (en) | 2018-12-19 |
US20200071311A1 (en) | 2020-03-05 |
CN108884046B (zh) | 2021-11-09 |
WO2017137535A1 (en) | 2017-08-17 |
AU2017218530A1 (en) | 2018-08-09 |
ES2786948T3 (es) | 2020-10-14 |
CN108884046A (zh) | 2018-11-23 |
AR107570A1 (es) | 2018-05-09 |
GB201602527D0 (en) | 2016-03-30 |
RU2018127494A (ru) | 2020-03-12 |
EP3414228B1 (en) | 2020-03-18 |
KR20180105726A (ko) | 2018-09-28 |
JP2019504858A (ja) | 2019-02-21 |
BR112018016396B1 (pt) | 2023-11-14 |
US10457674B2 (en) | 2019-10-29 |
UY37121A (es) | 2017-09-29 |
JP6916195B2 (ja) | 2021-08-11 |
CA3013404A1 (en) | 2017-08-17 |
US10793559B2 (en) | 2020-10-06 |
TW201738238A (zh) | 2017-11-01 |
US20190040051A1 (en) | 2019-02-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112016008468A2 (pt) | Composto de fórmula, composição farmacêutica, composto, uso de um composto e método para o tratamento ou melhora de câncer | |
CL2018000374A1 (es) | Sales de un inhibidor de lsd1 | |
BR112019001607A2 (pt) | inibidores macrocíclicos de quinases | |
BR112019003504A2 (pt) | compostos de amino-pirrolopirimidinona e métodos de uso dos mesmos | |
BR112019006712A2 (pt) | composto, composição farmacêutica, composição para uso no tratamento de uma doença, elemento implantável, e, dispositivo. | |
EA201692249A1 (ru) | Ингибиторы фосфатидилинозитол-3-киназы | |
BR112016015449A8 (pt) | compostos inibidores terapêuticos, composição farmacêutica os compreendendo e uso dos mesmos | |
BR112015006990A2 (pt) | composto, composição farmacêutica, e, uso de pelo menos um composto | |
BR112016015365A8 (pt) | composto, composição farmacêutica e uso de um composto | |
BR112016000489A8 (pt) | composto, composição farmacêutica que o compreende, uso da composição e métodos para fabricar compostos | |
BR112016015706A8 (pt) | composto, uso do mesmo e composição farmacêutica | |
EA201692265A1 (ru) | Ингибиторы фосфатидилинозитол-3-киназы | |
EA201692487A1 (ru) | Ингибиторы фосфатидилинозитол-3-киназы | |
EA201692266A1 (ru) | Ингибиторы фосфатидилинозитол-3-киназы | |
BR112016028642A2 (pt) | composto, composição farmacêutica, método de tratamento de uma doença ou condição, método de inibição da atividade de um polipeptídeo de fosfatidilinositol 3-quinase, método de inibição de reações imunes ou crescimento excessivo ou destrutivo ou de proliferação de células cancerosas, kit, e, uso de um composto, de um sal, de um isômero ou de uma mistura farmaceuticamente aceitável do mesmo. | |
EA201692480A1 (ru) | Фармацевтическая композиция | |
BR112018070123A2 (pt) | oxiesterós e métodos de uso dos mesmos | |
EA201890331A1 (ru) | Пиридинондикарбоксамиды для применения в качестве ингибиторов бромодомена | |
EA201692267A1 (ru) | Ингибиторы фосфатидилинозитол-3-киназы | |
BR112015030515A2 (pt) | intensificadores de inibidores de homólogo 2 de zeste | |
BR112017004589A2 (pt) | composto, composição farmacêutica, método para tratar um paciente, uso de um composto, kit, e método para tratar um distúrbio mediado por proteína smyd | |
BR112017025781A2 (pt) | derivados de 2-(pirazolopiridin-3-il)pirimidina como inibidores de jak | |
BR112017002852A2 (pt) | compostos de azetidiniloxifenilpirrolidina | |
BR112018006545A2 (pt) | ?composto, composição farmacêutica, combinação, uso de um composto, e, método para tratamento de uma doença ou condição? | |
ECSP16008797A (es) | Derivados de heterobicicloaril como inhibidores rorc2 y métodos de uso de los mismos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 10/02/2017, OBSERVADAS AS CONDICOES LEGAIS |